Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
This study has been terminated.
(Please see Detailed Description below for termination reason.)
First Posted: October 4, 2005
Last Update Posted: October 3, 2007
Information provided by:
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Tolerability Of Indiplon Therapy Initiated With Sertraline Versus Sertraline Monotherapy In Subjects With Insomnia And Co-Existing Major Depressive Disorder|
Resource links provided by NLM:
Further study details as provided by Neurocrine Biosciences:
Primary Outcome Measures:
- Change from baseline to week 1 in subjective total sleep time (sTST); (average of the week one data)
Secondary Outcome Measures:
- Change from baseline in subjective total sleep time (sTST). Change from baseline in subjective parameters: LSO, sWASO, sNAASO, Sleep Quality (IVR). Change from baseline in the 3-item HAM-D insomnia factor (items #4-6).
|Study Start Date:||November 2005|
|Estimated Study Completion Date:||April 2006|
This Pfizer run study stopped due to the co-development program for indiplon being terminated between Pfizer and Neurocrine. The study was terminated on 16 November 2006. There were no safety issues leading to the decision to terminate this study.
Contacts and Locations
No Contacts or Locations Provided